Sukhatme Mayukh 4
4 · Roivant Sciences Ltd. · Filed Dec 31, 2025
Insider Transaction Report
Form 4
Sukhatme Mayukh
DirectorPresident & CIO
Transactions
- Exercise/Conversion
Common Shares
2025-12-29$12.68/sh+748,358$9,489,179→ 19,584,905 total - Sale
Common Shares
2025-12-29$21.74/sh−311,873$6,780,119→ 19,273,032 total - Other
Common Shares
2025-12-29$21.74/sh−436,485$9,489,184→ 18,836,547 total - Exercise/Conversion
Common Shares
2025-12-31$12.68/sh+2,449,877$31,064,440→ 21,286,424 total - Sale
Common Shares
2025-12-31$21.71/sh−1,018,995$22,122,381→ 20,267,429 total - Other
Common Shares
2025-12-31$21.71/sh−1,430,882$31,064,448→ 18,836,547 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-29−748,358→ 555,840 totalExercise: $12.68Exp: 2026-03-31→ Common Shares (748,358 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-31−2,449,877→ 95,718 totalExercise: $12.68Exp: 2026-03-31→ Common Shares (2,449,877 underlying)
Footnotes (5)
- [F1]All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- [F2]These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive.
- [F3]These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive.
- [F4]Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
- [F5]Award of stock options to purchase Common Shares that is fully vested.